Friday’s Focus is Here: See Why (CODX) Just Popped On My Early Radar

Any content you receive is for information purposes only. Always conduct your own research.  *Sponsored Paul Prescott Just Put Co-Diagnostics, Inc. (Nasdaq: CODX) On The Top of This Morning's Watchlist—Friday, March 20, 2026 Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Full Coverage On (CODX) Begins Now Get (CODX) On Your Screen While It's Still Early… March 20, 2026 Friday's Focus is Here | See Why (CODX) Just Popped On My Early Radar Dear Reader, The global molecular diagnostics sector is approaching a pivotal shift that could reshape how medical testing is delivered. Advances in portable PCR systems, digital integration, and faster processing are pushing high-accuracy testing closer to the patient. As healthcare providers place greater emphasis on rapid answers, decentralized platforms are drawing increased attention across clinical and at-home settings. This trend is unfolding against the backdrop of a sizable infectious respiratory disease diagnostics market, which is projected to reach $91.8B by 2034, according to Global Insight Services. Companies working to close the gap between laboratory precision and everyday accessibility are now coming into sharper focus. Co-Diagnostics, Inc. (Nasdaq: CODX) is navigating this shift by developing a patented platform designed to bring laboratory-grade PCR accuracy into the home and point-of-care settings. Which is exactly why (CODX) is topping my watchlist this morning—Friday, March 20, 2026. But keep in mind, (CODX) has less than 2M shares listed as available to the public. When companies have small public floats like this, the potential exists for big moves if demand begins to shift. In fact, (CODX) recently made an approximate 108% move, practically overnight, from around $2.11 on March 9 to $4.40 the very next day. And when you combine that kind of momentum with a company tied to a fast-growing healthcare theme, a proprietary platform, and fresh market attention, it starts to become clear why this is a name readers will want to watch very closely right now. That growing sense of anticipation becomes even more compelling once you look at the technology, the platform design, and the broader vision beginning to take shape behind the scenes. By integrating advanced biochemistry with smartphone-ready hardware, this Utah-based firm is attempting to redefine the diagnostic landscape. The Democratization of Molecular Testing Co-Diagnostics, Inc. (Nasdaq: CODX) functions as a molecular diagnostics powerhouse that develops, manufactures, and markets innovative technologies utilized for the detection of nucleic acid molecules like DNA and RNA. Unlike traditional diagnostic models that rely on massive, centralized laboratory infrastructures and multi-day shipping delays, (CODX) utilizes proprietary Co-Primers™ technology to deliver high-speed results. This technology is the cornerstone of their platform, designed to enhance the specificity and sensitivity of polymerase chain reaction (PCR) testing—the industry's "gold standard"—while reducing the likelihood of primer-dimer interference that often plagues lesser systems. The company officially regained compliance with Nasdaq listing requirements on March 11, 2026, a move that restored its standing on a major national exchange and provided the transparency and liquidity essential for its next phase of growth. This regulatory milestone comes at a pivotal time as (CODX) advances its Co-Dx PCR Pro™ instrument, a compact, 2-pound device designed for decentralized environments. By allowing for "gold-standard" testing in clinics, offices, or even homes, the company is targeting a future where diagnostic delays no longer dictate patient outcomes. Market Potential and Pipeline Drivers The global market for infectious respiratory disease diagnostics is witnessing robust expansion, with molecular diagnostics—particularly PCR-based testing—holding a commanding 45% market share in 2024. Co-Diagnostics, Inc. (Nasdaq: CODX) is positioning itself at the intersection of this growth by initiating clinical evaluations for its upper respiratory multiplex test. This test is designed to simultaneously detect and differentiate between Flu A/B, CO-VID-19, and RSV—a "multiplex" approach that is increasingly demanded by healthcare providers who need to clear confusion during peak respiratory seasons. Furthermore, the company's pipeline extends far beyond common seasonal viruses. With a heavy focus on high-impact global health issues, (CODX) is developing tests for tuberculosis (TB), HPV, and even Zika virus. These applications are particularly relevant in emerging markets, where centralized labs are often inaccessible. By providing a portable PCR platform that can operate via a simple mobile app, the company is effectively creating a "lab-in-a-box" that can be deployed anywhere in the world, from rural clinics in India to suburban pharmacies in the United States. Intellectual Property and Global Scaling Intellectual property is the primary moat protecting the CODX ecosystem. In March 2026, the company was granted a Japanese patent covering fundamental systems and methods for its automated biological analysis. This follows a similar grant in Australia in late 2025, signaling a coordinated international strategy to protect its Co-Dx PCR platform in key global markets. This robust patent portfolio is not just a defensive measure; it is a foundational asset that enhances the company's ability to pursue high-value partnerships and licensing opportunities worldwide. The company's global reach is further amplified through its Indian joint venture, CoSara Diagnostics. This partnership has been a standout operational achievement, recently securing an ISO 13485 certification and a manufacturing license for the PCR Pro instrument from Indian regulatory bodies. This allows CODX to leverage local manufacturing efficiencies and distribution networks in one of the world's most populous regions, where affordable diagnostics are a matter of critical national importance. This strategy of "localizing" technology ensures that the company can scale without the prohibitive overhead of building its own international infrastructure from scratch. Operational Achievements and Financial Strategy Strategically, Co-Diagnostics, Inc. (Nasdaq: CODX) has focused on securing non-dilutive funding to drive its R&D. The company has been awarded millions in grants from the Bill & Melinda Gates Foundation specifically to develop accessible tuberculosis testing. These grants, including a recent $8.9M aw-ard, underscore the clinical validity of the platform and provide a significant financial runway as the company navigates the rigorous FDA 510(k) clearance process. As of late 2025, the company reported a preliminary cash balance of approximately $11.9M, giving them the "dry powder" needed to see their primary clinical objectives through to completion. The management team, led by Founder and CEO Dwight Egan, has emphasized a "disciplined growth" model that prioritizes regulatory clearance and commercialization of the point-of-care platform. With over 12 years at the helm, Egan has steered the company through the volatility of the pandemic era and into a more sustainable, diversified diagnostics model. The team is also integrating artificial intelligence through a new AI business unit, which is expected to increase operational efficiency and potentially reduce the time-to-market for future diagnostic tests. Recent Corporate Developments Mar 17, 2026 Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast Mar 16, 2026 Co-Diagnostics to Present at Medical Korea 2026 Mar 12, 2026 Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies Feb 9, 2026 Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai Feb 5, 2026 Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument Feb 4, 2026 Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform Jan 12, 2026 Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships 7 Reasons Why (CODX) is Topping My Watchlist This Morning —Friday, March 20, 2026… 1. Low Float: with fewer than 2M shares available to the public, (CODX)'s small float could have the potential to witness big moves if demand begins to shift. 2. Recent Momentum: after making an approximately 108% move from around $2.11 to $4.40 practically overnight, (CODX) has already demonstrated its ability for quick moves 3. PCR Platform: through its proprietary Co-Primers™ technology, (CODX) is advancing high-speed, high-specificity PCR testing within a compact system. 4. Expanding Pipeline: by developing multiplex respiratory tests along with TB, HPV, and Zika detection, (CODX) is targeting multiple high-impact diagnostic needs. 5. Global Footprint: supported by patents in Japan and Australia and an active India-based joint venture, (CODX) is building an international presence for its platform. 6. Patent Protection: with recent patent grants in Japan and Australia covering its PCR platform, (CODX) is strengthening its intellectual property position across key global markets. 7. Backed by Gates: with Gates Foundation support that includes a recent $8.9M award, (CODX) has secured outside funding tied to its tuberculosis testing work. Get (CODX) On Your Screen While It's Still Early… When you step back and look at the full picture, (CODX) brings together several elements that are difficult to ignore. A tightly held float, combined with a recent approx. 108% move in less than 24 hours, shows how quickly attention can shift. At the same time, its proprietary Co-Primers™ platform is designed to deliver fast, high-specificity PCR testing in a compact format, while an expanding pipeline targets multiple high-impact diagnostic areas. Add in global patent protection across key regions, an active international presence through its India joint venture, and support from the Gates Foundation—including a recent $8.9M aw-ard—and you begin to see why this company has landed on our radar. We have all eyes on (CODX) this morning. Get (CODX) on your radar while it's still early Also, keep a lookout for my next update, it could be hitting before the bell rings. Sincerely, Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter Street-Ideas.com ("Street-Ideas" or "SI" ) is owned by 147 Media LLC, a single member limited liability company. Data is provided from third-party sources and SI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between 147 Media LLC and TD Media LLC, 147 Media LLC has been hired for a period beginning on 03/19/2026 and ending on 03/20/2026 to publicly disseminate information about (CODX:US) via digital communications. Under this agreement, TD Media LLC has paid 147 Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither 147 Media LLC, TD Media LLC and their member own shares of (CODX:US). Please see important disclosure information here: https://street-ideas.com/disclosure/codx-GguGM/#details

Street Ideas | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe Update Profile | About our service provider Sent by paul@street-ideas.com